Table 1.
Baseline patient demographics and disease characteristics
| Abiraterone Acetate + Prednisone | |
|---|---|
| Enrolled patients, N (%) | 131 |
| Age, years | |
| Median (range) | 72.0 (48.0, 90.0) |
| Race, n (%) | |
| White | 108 (82.4) |
| Black | 19 (14.5) |
| Asian | 2(1.5) |
| Other | 1 (0.8) |
| Not reported | 1 (0.8) |
| Screening PSA, ng/mL | |
| Median (range) | 11.9 (1.3, 167.8) |
| ≥10 | 79 (60.3) |
| <10 | 52 (39.7) |
| PSADT, n (%) | 52 (39.7) |
| Median (range), months | 3.4(1.1, 9.4) |
| Primary tumor stage at initial diagnosis, n (%) | 119 |
| 1 | 39 (32.8) |
| 2 | 44 (37.0) |
| 3 | 36 (30.3) |
| 4 | 0 |
| Time from initial diagnosis to first dose of AA, years | |
| Median (range) | 10.2 (1.5, 26.0) |
| Time from 1st castration* to first AA dose, n (%) | 130 (99.2) |
| Median (range), years | 5.9(0.1, 26.0) |
| ECOG performance status | |
| 0 | 112 (85.5) |
| 1 | 18 (13.7) |
| 2 | 1 (0.8) |
| Calculated Gleason Score, n (%) | 125 (95.4) |
| <7 | 17 (13.6) |
| 7 | 59 (47.2) |
| ≥8 | 49 (39.2) |
| Median (range) | 7.0 (4.0; 10.0) |
*
Castration via surgery or gonadotropin-releasing hormone.
AA, abiraterone acetate; PSADT, prostate-specific antigen doubling time